Compare · AVTR vs PACB
AVTR vs PACB
Side-by-side comparison of Avantor Inc. (AVTR) and Pacific Biosciences of California Inc. (PACB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVTR and PACB operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- AVTR is the larger of the two at $5.43B, about 10.9x PACB ($496.8M).
- Over the past year, AVTR is down 38.2% and PACB is up 40.4% - PACB leads by 78.6 points.
- AVTR has been more active in the news (8 items in the past 4 weeks vs 6 for PACB).
- AVTR has more recent analyst coverage (25 ratings vs 24 for PACB).
- Company
- Avantor Inc.
- Pacific Biosciences of California Inc.
- Price
- $7.95-1.79%
- $1.60+0.63%
- Market cap
- $5.43B
- $496.8M
- 1M return
- +2.32%
- +19.40%
- 1Y return
- -38.22%
- +40.35%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- 2010
- News (4w)
- 8
- 6
- Recent ratings
- 25
- 24
Avantor Inc.
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, and clinical trial kits. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Pacific Biosciences of California Inc.
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a collaboration with Invitae Corporation to develop ultra-high-throughput clinical whole genome sequencing platform; and a research collaboration with Rady Children's Institute for Genomic Medicine for whole genome sequencing platform. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Latest AVTR
- SEC Form 10-Q filed by Avantor Inc.
- Avantor Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Avantor® Reports First Quarter 2026 Results
- Avantor Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Avantor® Announces Ludovic Brellier as Executive Vice President, Bioscience & Medtech Products (BMP) & Chief Transformation Officer
- Avantor® Unifies Masterflex® Portfolio to Streamline Fluid Management from R&D to Bioprocess Manufacturing
- Avantor® Enhances U.S. Biomanufacturing Infrastructure with Expanded Stability and Microbial Testing Facility
- SEC Form 4 filed by Eck Steven W
- Avantor® to Report First Quarter 2026 Earnings on Wednesday, April 29, 2026
- Avantor Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
Latest PACB
- SEC Form DEFA14A filed by Pacific Biosciences of California Inc.
- SEC Form DEF 14A filed by Pacific Biosciences of California Inc.
- PacBio and Lucid Genomics Announce Compatibility Collaboration to Advance Tertiary Analysis for Long-Read Sequencing
- PacBio to Report First Quarter 2026 Financial Results on May 7, 2026
- PacBio and Covaris Announce Joint Workflow Enabling HiFi Long-Read Sequencing of FFPE Tumor Samples
- SEC Form 4 filed by Gibson Christopher
- SEC Form 4 filed by Gibson James R Ii
- Amendment: SEC Form SCHEDULE 13G/A filed by Pacific Biosciences of California Inc.
- Basecamp Research Selects PacBio HiFi Sequencing to Power Trillion Gene Atlas Initiative
- Pacific Biosciences of California Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure